Leaflet:information for the user
Amlodipino/Valsartán/Hidroclorotiazida Combix 5 mg/160 mg/12,5 mg film-coated tablets
Amlodipino/Valsartán/Hidroclorotiazida Combix 10 mg/160 mg/12,5 mg film-coated tablets
Amlodipino/Valsartán/Hidroclorotiazida Combix 5 mg/160 mg/25 mg film-coated tablets
Amlodipino/Valsartán/Hidroclorotiazida Combix 10 mg/160 mg/25 mg film-coated tablets
Amlodipino/Valsartán/Hidroclorotiazida Combix 10 mg/320 mg/25 mg film-coated tablets
amlodipino/valsartán/hidroclorotiazida
Read this leaflet carefully before you start to take this medicine,because it contains important information for you.
1.What is Amlodipino/Valsartán/Hidroclorotiazida Combix and for what it is used
2.What you need to knowbeforestarting totake Amlodipino/Valsartán/Hidroclorotiazida Combix
3.How to take Amlodipino/Valsartán/Hidroclorotiazida Combix
4.Possible side effects
5Storage of Amlodipino/Valsartán/Hidroclorotiazida Combix
6.Contents of the pack and additional information
Amlodipino/Valsartán/Hidroclorotiazida Combixtablets contain three substances called amlodipino, valsartán and hidroclorotiazida. All these substances help to control high blood pressure.
As a result of the three mechanisms, blood vessels relax and blood pressure decreases.
Amlodipino/Valsartán/Hidroclorotiazida Combixis used to treat high blood pressure in adult patients whose blood pressure is already controlled while taking amlodipino, valsartán and hidroclorotiazida and who may benefit from taking a tablet that contains the three substances.
Do not take Amlodipino/Valsartán/Hidroclorotiazida Combix
If you think you may be allergic, do not take this medication and inform your doctor.
Do not take Amlodipino/Valsartán/Hidroclorotiazida Combix and inform your doctor if you are affected by any of the above cases.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication
Your doctor may monitor your renal function, blood pressure, and electrolyte levels (such as potassium) in the blood at regular intervals.
See also the information under the heading "Do not take Amlodipino/Valsartán/Hidroclorotiazida Combix".
Inform your doctor if you are affected by any of the cases mentioned.
Children and adolescents
This medication is not recommended for use in children or adolescents under 18 years old.
Older adults (65 years and older)
This medication may be used in people 65 years and older at the same dose as used in other adults and in the same way as they have already taken the three substances called amlodipino, valsartán, and hidroclorotiazida. Renal pressure should be monitored regularly in elderly patients, particularly those taking the maximum dose of Amlodipino/Valsartán/Hidroclorotiazida Combix (10 mg/320 mg/25 mg).
Use of Amlodipino/Valsartán/Hidroclorotiazida Combix with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication. Your doctor may need to adjust your dose and/or take other precautions. In some cases, you may need to stop taking one of the medications. This is especially important if you are taking any of the medications listed below:
Do not take with:
Use with caution with:
medications that may induce "torsades de pointes" (irregular heart rhythm), such as antiarrhythmics (medications used to treat heart problems) and some antipsychotics;
medications that may reduce the amount of potassium in the blood, such as diuretics, corticosteroids, laxatives, amphotericin, or penicillin G;
St. John's Wort;
Take Amlodipino/Valsartán/Hidroclorotiazida Combix with food, drinks, and alcohol
People who have been prescribed this medication should not consume grapefruit or grapefruit juice.
This is because grapefruit and grapefruit juice may cause an increase in the blood levels of the active ingredient amlodipino, which may cause unpredictable reductions in blood pressure. Consult your doctor before drinking alcohol. Alcohol may significantly lower your blood pressure and/or increase the risk of dizziness or fainting.
Pregnancy and breastfeeding
Pregnancy
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medication.. Your doctor will usually advise you to stop taking this medication before becoming pregnant or as soon as you become pregnant, and recommend taking another antihypertensive medication instead. This medication is not recommended for use at the beginning of pregnancy and should not be administered after the third month of pregnancy as it may cause serious harm to your baby when administered from that point onwards.
Breastfeeding
Inform your doctorif you plan to start or are breastfeeding. It has been shown that amlodipino passes into breast milk in small amounts. This medication is not recommended for use during this period. Your doctor may decide to administer a treatment that is more suitable if you want to breastfeed, especially in newborns or premature babies.
Consult your doctor or pharmacist before using any medication.
Driving and operating machinery
As with other medications used to treat high blood pressure, this medication may cause you to feel dizzy, drowsy, nauseous, or experience headaches. If you experience these symptoms, do not drive or operate tools or machinery.
Use in athletes
This medication containshidroclorotiazidawhich may produce a positive result in doping control tests
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor again. This will help you obtain the best results and reduce the risk of adverse effects.
The usual dose ofAmlodipino/Valsartán/Hidroclorotiazida Combixisone tablet per day.
Depending on your response to treatment, your doctor may suggest a higher or lower dose.
Do not exceed the prescribed dose.
If you take moreAmlodipino/Valsartán/Hidroclorotiazida Combixthan you should
If you have accidentally taken too many tablets ofthis medication, consult your doctor immediately. You may need medical attention.
Excess fluid may accumulate in the lungs (pulmonary edema) causing difficulty breathing that may develop within 24-48 hours after ingestion.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested
If you forget to takeAmlodipino/Valsartán/Hidroclorotiazida Combix
If you forget to take a dose of this medication, take it as soon as you remember and then take the next dose at the usual time. If it is almost time for the next dose, you should only take the next tablet at the usual time.Do nottake a double dose (two tablets at once) to make up for the missed doses.
If you interrupt treatment withAmlodipino/Valsartán/Hidroclorotiazida Combix
Stopping your treatment withthis medicationmay cause your condition to worsen. Do not stop taking the medication unless your doctor tells you to.
Always take this medication, even if you feel well
People with hypertension often do not notice any symptoms of their problem. Many feel well. It is very important that you take this medication exactly as your doctor has instructed to obtain the best results and reduce the risk of adverse effects. Keep your appointments with your doctor even if you feel well.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
As with any combination that contains three active principles, it cannot be ruled out that side effects associated with each individual component may occur. The side effects observed with this medicine or one of its three active principles (amlodipine, valsartan, and hydrochlorothiazide) are listed below and may occur with the use of this medicine.
Some side effects can be severe and require immediate medical attention.
Consult your doctor immediately if, after taking this medicine, you experience any of the following severe side effects:
Frequent (may affect up to 1 in 10 patients):
Infrequent (may affect up to 1 in 100 patients):
Rare (may affect up to 1 in 1,000 patients):
Very rare (may affect up to 1 in 10,000 patients):
Other side effects may include:
Very frequent (may affect more than 1 in 10 patients)
Frequent (may affect up to 1 in 10 patients)
Infrequent (may affect up to 1 in 100 patients)
Rare (may affect up to 1 in 1,000 patients)
Very rare (may affect up to 1 in 10,000 patients)
Frequency unknown (the frequency cannot be estimated from available data)
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and blister after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 30°C
Do not use any packaging that is damaged or shows signs of manipulation.
Medications should not be disposed of through drains or in the trash. Deposit the packaging and medications you no longer need at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. In this way, you will help protect the environment.
5 mg/160 mg/12,5 mgfilm-coated tablets
Each film-coated tablet contains 5 mg of amlodipino (as amlodipino besilato), 160 mg of valsartán and 12,5 mg of hidroclorotiazida
10 mg/160 mg/12,5 mgfilm-coated tablets
Each film-coated tablet contains 10 mg of amlodipino (as amlodipino besilato), 160 mg of valsartán and 12,5 mg of hidroclorotiazida
5 mg/160 mg/25 mgfilm-coated tablets
Each film-coated tablet contains 5 mg of amlodipino (as amlodipino besilato), 160 mg of valsartán and 25 mg of hidroclorotiazida
10 mg/160 mg/25 mgfilm-coated tablets
Each film-coated tablet contains 10 mg of amlodipino (as amlodipino besilato), 160 mg of valsartán and 25 mg of hidroclorotiazida
10 mg/320 mg/25 mgfilm-coated tablets
Each film-coated tablet contains 10 mg of amlodipino (as amlodipino besilato), 320 mg of valsartán and 25 mg of hidroclorotiazida
The other components are:
Microcrystalline cellulose
Crospovidona
Colloidal silicon dioxide
Estearato de magnesio
Hipromelosa 6 cPs
Macrogol 4000
Talco
Dióxido de titanio (E171)(only in 5 mg/160 mg/12,5 mg film-coated tablets, 10 mg/160 mg/12,5 mg film-coated tablets, 5 mg/160 mg/25 mg tablets)
Óxido de hierro rojo (E172) (only in 10 mg/160 mg/12,5 mg film-coated tablets)
Óxido de hierro amarillo (E172)(only in 10 mg/160 mg/12,5 mg film-coated tablets, 5 mg/160 mg/25 mg film-coated tablets, 10 mg/160 mg/25 mg film-coated tablets, 10 mg/320 mg/25 mg film-coated tablets)
Appearance of the product and contents of the package
The Amlodipino/Valsartán/Hidroclorotiazida Combix 5 mg/160 mg/12,5 mg film-coated tabletsare biconvex, oval, white, marked with “T23” on one side and smooth on the other.
The Amlodipino/Valsartán/Hidroclorotiazida Combix 5 mg/160 mg/25 mg film-coated tabletsare biconvex, oval, yellow, marked with “T25” on one side and smooth on the other.
The Amlodipino/Valsartán/Hidroclorotiazida Combix 10 mg/160 mg/12,5 mg film-coated tabletsare biconvex, oval, pale yellow, marked with “C96” on one side and smooth on the other.
The Amlodipino/Valsartán/Hidroclorotiazida Combix 10 mg/160 mg/25 mg film-coated tabletsare biconvex, oval, yellow-brown, marked with “C97” on one side and smooth on the other.
The Amlodipino/Valsartán/Hidroclorotiazida Combix 10 mg/320 mg/25 mg film-coated tabletsare biconvex, oval, yellow-brown, marked with “T98” on one side and smooth on the other.
The following pack sizes are available: boxes with blisters of 14, 28, 56 and 98 film-coated tablets.
Only some package sizes may be marketed.
Marketing authorization holder and manufacturer responsible
Marketing authorization holder
Laboratorios Combix, S.L.U.
C/ Badajoz 2, Edificio 2
28223 Pozuelo de Alarcón (Madrid)
Spain
Manufacturer responsible
Synoptis Industrial Sp. z o.o
ul. Rabowicka 15, Swarzedz,
62-020, Poland
or
Focus Care Pharmaceuticals B.V.
Westzijde 416, 1506 GM Zaandam
Netherlands
or
Heumann Pharma GmbH & Co. Generica KG
Südwestpark 50
90449 Nürnberg
Germany
or
Laboratori FUNDACIO DAU,
C/ De la letra C, 12-14,
Poligono Industrialde la Zona Franca,
08040 Barcelona,
Spain
Last revision date of thisleaflet:January 2022
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/)
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.